Amicus Therapeutics, Inc.

BMV:FOLD * Stock Report

Market Cap: Mex$58.4b

Amicus Therapeutics Management

Management criteria checks 2/4

Amicus Therapeutics' CEO is Brad Campbell, appointed in Jan 2015, has a tenure of 8.25 years. total yearly compensation is $4.91M, comprised of 11.2% salary and 88.8% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth MX$84.57M. The average tenure of the management team and the board of directors is 6.1 years and 5.8 years respectively.

Key information

Brad Campbell

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage11.2%
CEO tenure8.3yrs
CEO ownership0.1%
Management average tenure6.1yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brad Campbell's remuneration changed compared to Amicus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-US$237m

Sep 30 2022n/an/a

-US$264m

Jun 30 2022n/an/a

-US$281m

Mar 31 2022n/an/a

-US$270m

Dec 31 2021US$5mUS$551k

-US$250m

Sep 30 2021n/an/a

-US$239m

Jun 30 2021n/an/a

-US$252m

Mar 31 2021n/an/a

-US$254m

Dec 31 2020US$5mUS$516k

-US$277m

Sep 30 2020n/an/a

-US$295m

Jun 30 2020n/an/a

-US$293m

Mar 31 2020n/an/a

-US$325m

Dec 31 2019US$4mUS$501k

-US$356m

Sep 30 2019n/an/a

-US$345m

Jun 30 2019n/an/a

-US$442m

Mar 31 2019n/an/a

-US$419m

Dec 31 2018US$3mUS$468k

-US$349m

Sep 30 2018n/an/a

-US$340m

Jun 30 2018n/an/a

-US$293m

Mar 31 2018n/an/a

-US$279m

Dec 31 2017US$2mUS$450k

-US$284m

Sep 30 2017n/an/a

-US$273m

Jun 30 2017n/an/a

-US$208m

Mar 31 2017n/an/a

-US$211m

Dec 31 2016US$2mUS$427k

-US$200m

Compensation vs Market: Brad's total compensation ($USD4.91M) is above average for companies of similar size in the MX market ($USD1.61M).

Compensation vs Earnings: Brad's compensation has increased whilst the company is unprofitable.

CEO

Brad Campbell (46 yo)

8.3yrs

Tenure

US$4,911,455

Compensation

Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...

Leadership Team

NamePositionTenureCompensationOwnership
John Crowley
Executive Chairman18.7yrsUS$9.99m0.37%
MX$ 214.1m
Bradley Campbell
CEO, President & Director8.3yrsUS$4.91m0.14%
MX$ 84.6m
Daphne Quimi
Chief Financial Officer4.3yrsUS$3.06m0.088%
MX$ 51.5m
Ellen Rosenberg
Chief Legal Officer & Corporate Secretary7.2yrsUS$3.05m0.049%
MX$ 28.7m
David Clark
Chief People Officer4.5yrsUS$2.62m0.039%
MX$ 22.5m
Samantha Prout
VP, Global Controller & Principal Accounting Officer5.1yrsno data0.029%
MX$ 17.1m
Jill Weimer
Chief Science Officerno datano datano data
Andrew Faughnan
Senior Director of Investor Relationsno datano datano data
Patrik Florencio
Global Chief Compliance & Risk Officer7.7yrsno datano data
Diana Moore
Head of Global Corporate Communicationsno datano datano data
Jayne Gershkowitz
Chief Patient Advocate7.6yrsno datano data
Jeffrey Castelli
Chief Development Officerno datano data0.078%
MX$ 45.5m

6.1yrs

Average Tenure

52.5yo

Average Age

Experienced Management: FOLD *'s management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Crowley
Executive Chairman18.7yrsUS$9.99m0.37%
MX$ 214.1m
Bradley Campbell
CEO, President & Director4.8yrsUS$4.91m0.14%
MX$ 84.6m
Burke Whitman
Independent Director3.8yrsUS$390.00k0.022%
MX$ 13.0m
Michael Kelly
Independent Director2.3yrsUS$390.00k0.0051%
MX$ 3.0m
Glenn Sblendorio
Independent Director16.8yrsUS$402.50k0.016%
MX$ 9.5m
Margaret McGlynn
Independent Director13.5yrsUS$400.00k0.0056%
MX$ 3.3m
Craig Wheeler
Independent Director6.8yrsUS$394.99k0.011%
MX$ 6.4m
Michael Raab
Lead Independent Director19.3yrsUS$428.28k0.017%
MX$ 9.8m
Eiry Roberts
Independent Director1.8yrsUS$522.36k0.0020%
MX$ 1.2m
Lynn Bleil
Independent Director4.6yrsUS$395.00k0.013%
MX$ 7.9m

5.8yrs

Average Tenure

60.5yo

Average Age

Experienced Board: FOLD *'s board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/28 13:50
End of Day Share Price 2023/01/29 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amicus Therapeutics, Inc. is covered by 28 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Michael UlzBaird
Yun ZhongBerenberg